Boehringer Ingelheim
Clinical trials sponsored by Boehringer Ingelheim, explained in plain language.
-
Can a weekly shot tame blood sugar in type 2 diabetes?
Disease control Not yet recruitingThis phase 3 trial asks whether survodutide, an investigational weekly injection, can help adults with type 2 diabetes lower their blood sugar more than a placebo. Around 600 participants, who also follow diet and exercise or take standard diabetes medications (including insulin)…
Phase: PHASE3 • Sponsor: Boehringer Ingelheim • Aim: Disease control
Last updated Aug 12, 2026 00:00 UTC
-
Can a new injection help tackle obesity? a trial investigates
Disease control Not yet recruitingThis early-stage trial is testing an investigational drug called BI 3034701 in people with overweight or obesity who also have at least one weight-related health condition. The main goal is to see how safe and tolerable the drug is when given by injection, and to understand how i…
Phase: PHASE1 • Sponsor: Boehringer Ingelheim • Aim: Disease control
Last updated Aug 12, 2026 00:00 UTC
-
New pill aims to halt lung scarring in thousands
Disease control Not yet recruitingThis study tests a drug called nerandomilast in 466 adults with fibrosing interstitial lung disease (ILD) who are at risk of worsening. Participants take either the drug or a placebo for at least 52 weeks. Doctors measure lung function and use CT scans to see if the drug slows di…
Phase: PHASE3 • Sponsor: Boehringer Ingelheim • Aim: Disease control
Last updated Aug 08, 2026 00:03 UTC
-
Experimental drug duo aims to boost immune attack on tough cancers
Disease control Not yet recruitingThis study tests a combination of two experimental drugs, obrixtamig and ZL-1310, designed to help the immune system fight cancer. It is for adults with advanced small cell lung cancer or other neuroendocrine cancers. The trial has two parts: the first finds a safe dose of the tw…
Phase: PHASE1, PHASE2 • Sponsor: Boehringer Ingelheim • Aim: Disease control
Last updated Aug 07, 2026 00:00 UTC
-
Can a new drug rally the immune system against Hard-to-Treat cancers?
Disease control Not yet recruitingThis early-stage trial tests an experimental medicine called BI 3822971 in adults with advanced or metastatic solid cancers, such as lung, head and neck, breast, esophageal, bladder, vulvar, or cervical cancer, who have no standard treatment options left. The goal is to find out …
Phase: PHASE1 • Sponsor: Boehringer Ingelheim • Aim: Disease control
Last updated Aug 06, 2026 00:00 UTC
-
5,000-Patient study tests jardiance against standard heart failure drugs in china
Disease control Not yet recruitingThis study looks at how well the drug Jardiance works compared to other standard heart failure treatments in Chinese patients with a specific type of heart failure (HFrEF). Researchers will track about 5,000 adults to see which treatment better prevents heart failure hospitalizat…
Sponsor: Boehringer Ingelheim • Aim: Disease control
Last updated Jun 27, 2026 09:06 UTC
-
Can a new drug keep the Heart's beat steady? trial puts verducatib to the test
Knowledge-focused Not yet recruitingThis Phase 1 trial is testing whether an experimental drug called verducatib affects the heart's electrical activity, specifically the QT interval, which is a measure of heart rhythm safety. Healthy adults aged 18 to 50 will receive multiple doses of verducatib, a placebo, or mox…
Phase: PHASE1 • Sponsor: Boehringer Ingelheim • Aim: Knowledge-focused
Last updated Aug 14, 2026 00:00 UTC
-
Can two factories make the same Parkinson's drug? a trial puts it to the test
Knowledge-focused Not yet recruitingThis trial investigates whether pramipexole tablets produced at two different manufacturing sites are processed identically by the body. Healthy volunteers aged 18 to 55 take both versions in a crossover design, and researchers compare drug levels in the blood. The goal is to con…
Phase: PHASE1 • Sponsor: Boehringer Ingelheim • Aim: Knowledge-focused
Last updated Jul 29, 2026 00:00 UTC
-
Radioactive tracer reveals how experimental drug BI 3034701 leaves the body
Knowledge-focused Not yet recruitingThis early-phase trial investigates how healthy male volunteers process and eliminate a single dose of the experimental drug BI 3034701. Eight men with normal weight or overweight will receive the drug mixed with a tiny amount of radioactive tracer, allowing researchers to track …
Phase: PHASE1 • Sponsor: Boehringer Ingelheim • Aim: Knowledge-focused
Last updated Jul 18, 2026 00:00 UTC
-
Jardiance under the microscope: new study tracks heart failure outcomes in china
Knowledge-focused Not yet recruitingThis study will observe 3,000 adults in China with a type of heart failure called HFpEF who are starting the drug Jardiance. Researchers will track how many patients are hospitalized for heart failure or die from heart-related causes over time. The goal is to see how effective an…
Sponsor: Boehringer Ingelheim • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:05 UTC